Analysts Set Carlsmed, Inc. (NASDAQ:CARL) PT at $19.67

Carlsmed, Inc. (NASDAQ:CARL) has received an average rating of “Hold” from the five analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $19.6667.

A number of research firms have issued reports on CARL. Wall Street Zen raised Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Truist Financial reduced their price target on Carlsmed from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, April 15th. Weiss Ratings reiterated a “sell (e-)” rating on shares of Carlsmed in a research report on Monday, December 22nd. Zacks Research upgraded Carlsmed from a “strong sell” rating to a “hold” rating in a research report on Thursday, March 26th. Finally, The Goldman Sachs Group reduced their price target on Carlsmed from $19.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, April 9th.

Carlsmed Stock Performance

NASDAQ:CARL opened at $10.94 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.87 and a quick ratio of 8.74. The business has a fifty day simple moving average of $11.18 and a two-hundred day simple moving average of $12.46. Carlsmed has a 1 year low of $8.50 and a 1 year high of $17.19. The company has a market capitalization of $292.43 million and a P/E ratio of -2.99.

Carlsmed (NASDAQ:CARL) last released its earnings results on Wednesday, February 25th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. Carlsmed had a negative return on equity of 72.60% and a negative net margin of 58.67%.The business had revenue of $15.16 million during the quarter, compared to the consensus estimate of $15.20 million. On average, analysts expect that Carlsmed will post -1.66 earnings per share for the current year.

Hedge Funds Weigh In On Carlsmed

Hedge funds have recently made changes to their positions in the stock. TD Waterhouse Canada Inc. purchased a new position in shares of Carlsmed in the third quarter valued at $2,026,000. Teacher Retirement System of Texas purchased a new position in shares of Carlsmed in the third quarter valued at $2,343,000. Monashee Investment Management LLC purchased a new position in shares of Carlsmed in the third quarter valued at $536,000. Ghisallo Capital Management LLC purchased a new position in shares of Carlsmed in the third quarter valued at $670,000. Finally, Kornitzer Capital Management Inc. KS purchased a new position in shares of Carlsmed in the third quarter valued at $736,000.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).